We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Involved in Scientific Research? Then you must have heard about MA-based Thermo Fisher Scientific, Inc. (TMO - Free Report) one of the leading scientific instrument manufacturers across the world. Interestingly for this acquisition-friendly company, the latest buy out of Life Technologies is expected to give birth to an unrivaled market leader serving research, Specialty Diagnostics and applied markets.
Currently, Thermo Fisher has a Zacks Rank #4 (Sell) but that could change following its impressive fourth-quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at $2.37 per share. Thermo Fisher’s adjusted earnings per share of $2.41 beat this estimate by 1.68%.
Full year adjusted earnings came in at $8.27 per share which has also surpassed the Zacks Consensus Estimate of $8.24 by 0.4%.
Thermo Fisher Scientific Inc Price and EPS Surprise
Revenues: Thermo Fisher posted revenues of $4,953.2 billion, which has missed the Zacks Consensus Estimate for revenues of $4,985 billion.
Full year revenues came in at $18.27 billion which has also missed the Zacks Consensus Estimate of $19.56 billion.
Key Stats: Among its four business segments, Thermo Fisher delivered fourth-quarter revenues of $1.34 billion (up 10%) in Life Sciences Solutions, $1.22 billion (up 32%) in Analytical Instruments, $834 million (down 3.5%) in Specialty Diagnostics and $1.76 billion (down 3.3%) in Laboratory Products and Services respectively. However on a full-year basis all the four segments have seen increase on year-over-year basis.
Major Factors: Management seemed upbeat about its successful execution of its capital deployment strategy to create value for its shareholders. We are also encouraged about the company’s acquisition of FEI, which is expected to add leading capabilities in electron microscopy that complement Thermo Fisher’s analytical instruments portfolio. In Asia-Pacific and emerging markets, Thermo Fisher has also leveraged its industry-leading scale to drive strong growth, especially in China.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Thermo Fisher earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher (TMO): Tops Q4 Earnings, Misses Revenues
Involved in Scientific Research? Then you must have heard about MA-based Thermo Fisher Scientific, Inc. (TMO - Free Report) one of the leading scientific instrument manufacturers across the world. Interestingly for this acquisition-friendly company, the latest buy out of Life Technologies is expected to give birth to an unrivaled market leader serving research, Specialty Diagnostics and applied markets.
Currently, Thermo Fisher has a Zacks Rank #4 (Sell) but that could change following its impressive fourth-quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at $2.37 per share. Thermo Fisher’s adjusted earnings per share of $2.41 beat this estimate by 1.68%.
Full year adjusted earnings came in at $8.27 per share which has also surpassed the Zacks Consensus Estimate of $8.24 by 0.4%.
Thermo Fisher Scientific Inc Price and EPS Surprise
Thermo Fisher Scientific Inc Price and EPS Surprise | Thermo Fisher Scientific Inc Quote
Revenues: Thermo Fisher posted revenues of $4,953.2 billion, which has missed the Zacks Consensus Estimate for revenues of $4,985 billion.
Full year revenues came in at $18.27 billion which has also missed the Zacks Consensus Estimate of $19.56 billion.
Key Stats: Among its four business segments, Thermo Fisher delivered fourth-quarter revenues of $1.34 billion (up 10%) in Life Sciences Solutions, $1.22 billion (up 32%) in Analytical Instruments, $834 million (down 3.5%) in Specialty Diagnostics and $1.76 billion (down 3.3%) in Laboratory Products and Services respectively. However on a full-year basis all the four segments have seen increase on year-over-year basis.
Major Factors: Management seemed upbeat about its successful execution of its capital deployment strategy to create value for its shareholders. We are also encouraged about the company’s acquisition of FEI, which is expected to add leading capabilities in electron microscopy that complement Thermo Fisher’s analytical instruments portfolio. In Asia-Pacific and emerging markets, Thermo Fisher has also leveraged its industry-leading scale to drive strong growth, especially in China.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Thermo Fisher earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>